Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Myasthenia Gravis 2

Interventions

pembrolizumab 589Cyclophosphamide 539Magnetic Resonance Spectroscopy 523Radiotherapy 506Specimen Handling 503Nivolumab 407Cisplatin 370Carboplatin 358Biopsy 304Blood Specimen Collection 295Radiosurgery 283Paclitaxel 274Surveys and Questionnaires 268Standard of Care 266Gemcitabine 265fludarabine 261Dexamethasone 258Drug Therapy 256venetoclax 246Bevacizumab 246Oxaliplatin 206Rituximab 195Capecitabine 194Radiation 189Fluorouracil 186Ipilimumab 184durvalumab 180Doxorubicin 175atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × efgartigimod alfa × 1 year × Clear all
NCT07072988 2025-09-24

OPTIMAGE

Centre Hospitalier Universitaire de Nice

Phase 4 Recruiting
50 enrolled

Myasthenia Gravis

NCT06765161 2025-07-29

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

Clinique Neuro-Outaouais

Phase 3 Recruiting
30 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡